Literature DB >> 10579653

Screening for fibrinolytic activity in eight Viperid venoms.

M S Ramírez1, E E Sánchez, C García-Prieto, J C Pérez, G R Chapa, M R McKeller, R Ramírez, Y De Anda.   

Abstract

Snake venoms contain direct-acting fibrinolytic metalloproteinases (MMP) that could have important applications in medicine. Fibrinolytic enzymes isolated from venom can induce in vitro clot lysis by directly acting on a fibrin clot. The most ideal fibrinolytic enzyme would have high affinity for clots, dissolve clots directly without causing hemorrhage, and would not be neutralized in vivo by endogenous metalloproteinase inhibitors. The purpose of this study was to compare DEAE/HPLC venom profiles from Viperid snakes and identify fractions that contain fibrinolytic activity with no hemorrhagic activity and are not neutralized by animal sera. The sera selected were from four (Virginia opossum, Gray woodrat, Mexican ground squirrel, and Hispid cottonrat) animals known to neutralize hemorrhagic activity in snake venoms. Nineteen fractions from the Viperid venoms had fibrinolytic activity. Agkistrodon venom fractions contained the highest specific fibrinolytic activities. A. piscivorus leucostoma fraction 4 contained a high specific fibrinolytic activity, no hemorrhagic activity, and the fibrinolytic activity was not neutralized by the proteinase inhibitors of the four animal sera. A. contortrix laticinctus fraction 1 also had a high specific fibrinolytic activity and no hemorrhagic activity. However, the fibrinolytic activity was neutralized by Didelphis virginiana (Virginia opossum) serum.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579653     DOI: 10.1016/s0742-8413(99)00056-0

Source DB:  PubMed          Journal:  Comp Biochem Physiol C Pharmacol Toxicol Endocrinol        ISSN: 1367-8280


  1 in total

1.  Southern copperhead venom enhances tissue-type plasminogen activator induced fibrinolysis but does not directly lyse human plasma thrombi.

Authors:  Vance G Nielsen
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.